Undisclosed selective CDK12/13 inhibitor
/ Chordia Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 01, 2026
Preclinical Evaluation of Selective CDK12/13 Inhibition in CDK12-Loss Prostate Cancer and Combination Approaches with DNA Damage-Targeting Therapies
(ESMO Asia 2026)
- No abstract available
Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CDK12
1 to 1
Of
1
Go to page
1